Icosavax's Return on Invested Capital Overview

Icosavax ICVX brought in sales totaling $582.00 thousand during Q1 according to data provided by Benzinga Pro. However, earnings decreased 29.43%, resulting in a loss of $23.53 million. In Q4, Icosavax brought in $2.07 million in sales but lost $18.18 million in earnings.

What Is ROIC?

Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly pre-tax profit relative to invested capital by a business. Generally, a higher ROIC suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Icosavax posted an ROIC of -9.11%.

It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly pre-tax profit relative to invested capital by a business. Generally, a higher ROIC suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Icosavax posted an ROIC of -9.11%.

It is important to keep in mind that ROIC evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

For Icosavax, a negative ROIC ratio of -9.11% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Icosavax reported Q1 earnings per share at $-0.6/share, which did not meet analyst predictions of $-0.49/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.